Overview
A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)
Status:
Completed
Completed
Trial end date:
2012-06-01
2012-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) model.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Aciex Therapeutics, Inc.Treatments:
Cetirizine
Criteria
Inclusion Criteria:- positive bilateral conjunctival allergen challenge (CAC) reaction
Exclusion Criteria:
- known contraindications or sensitivities to the study medication or its components
- any ocular condition that, in the opinion of the investigator, could affect the
subjects safety or trial parameters
- use of disallowed medication during the period indicated prior to the enrollment or
during the study